Barclays PLC Aurinia Pharmaceuticals Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Barclays PLC holds 219,331 shares of AUPH stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
219,331
Previous 76,259
187.61%
Holding current value
$1.78 Million
Previous $435,000
269.43%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding AUPH
# of Institutions
209Shares Held
58.7MCall Options Held
1.14MPut Options Held
1.51M-
Black Rock Inc. New York, NY9.27MShares$75.3 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY8.2MShares$66.6 Million1.0% of portfolio
-
Tang Capital Management LLC San Diego, CA7.23MShares$58.7 Million4.52% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$32.2 Million2.22% of portfolio
-
State Street Corp Boston, MA2.95MShares$23.9 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.15B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...